ESMO 2023 movers – who won and who lost?
The dust has settled on a momentous ESMO conference, which saw biotech activity amid big pharma’s practice-changing data.
The dust has settled on a momentous ESMO conference, which saw biotech activity amid big pharma’s practice-changing data.
The study of Novartis’s Pluvicto in pre-chemo prostate cancer is a bust on overall survival, with questions raised about trial design.
The presidential session heralds a combo of Padcev and Keytruda as the new front-line bladder cancer standard of care.